RAS Proteins and Their Regulators in Human Disease

Cell

Volumn 170, Issue 1, 2017, Pages 17-33

  Simanshu, Dhirendra K ^a   Nissley, Dwight V ^a   McCormick, Frank ^a,b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

CRAFT; KRAS; KRAS therapies; NF1; RAF1; RAS effectors; RAS in the membrane; RAS proteins; RAS driven cancer; RASopathies

Indexed keywords

RAS PROTEIN; REGULATOR PROTEIN;

AUTOSOMAL DOMINANT DISORDER; CAPILLARY MALFORMATION; DISEASES; GENE SWITCHING; HUMAN; MALIGNANT NEOPLASM; MENTAL DISEASE; MOLECULAR BIOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN TARGETING; RASOPATHY; REGULATORY MECHANISM; REVIEW; ANIMAL; CELL MEMBRANE; CHEMISTRY; CONGENITAL DISORDER; GENETICS; METABOLISM; MUTATION; NEOPLASM; PHYLOGENY; SIGNAL TRANSDUCTION; YEAST;

ANIMALS; CELL MEMBRANE; CONGENITAL ABNORMALITIES; HUMANS; MENTAL DISORDERS; MUTATION; NEOPLASMS; PHYLOGENY; RAS PROTEINS; SIGNAL TRANSDUCTION; YEASTS;

EID: 85021634621     PISSN: 00928674     EISSN: 10974172     Source Type: Journal    
DOI: 10.1016/j.cell.2017.06.009     Document Type: Review

References (155)

1. Abankwa, D., Gorfe, A.A., Inder, K., Hancock, J.F., Ras membrane orientation and nanodomain localization generate isoform diversity. Proc. Natl. Acad. Sci. USA 107 (2010), 1130–1135.
2. Ahmadian, M.R., Stege, P., Scheffzek, K., Wittinghofer, A., Confirmation of the arginine-finger hypothesis for the GAP-stimulated GTP-hydrolysis reaction of Ras. Nat. Struct. Biol. 4 (1997), 686–689.
3. Alvarez-Moya, B., López-Alcalá, C., Drosten, M., Bachs, O., Agell, N., K-Ras4B phosphorylation at Ser181 is inhibited by calmodulin and modulates K-Ras activity and function. Oncogene 29 (2010), 5911–5922.
4. Aoki, Y., Niihori, T., Inoue, S., Matsubara, Y., Recent advances in RASopathies. J. Hum. Genet. 61 (2016), 33–39.
5. Arafeh, R., Qutob, N., Emmanuel, R., Keren-Paz, A., Madore, J., Elkahloun, A., Wilmott, J.S., Gartner, J.J., Di Pizio, A., Winograd-Katz, S., et al. Recurrent inactivating RASA2 mutations in melanoma. Nat. Genet. 47 (2015), 1408–1410.
6. Athuluri-Divakar, S.K., Vasquez-Del Carpio, R., Dutta, K., Baker, S.J., Cosenza, S.C., Basu, I., Gupta, Y.K., Reddy, M.V.R., Ueno, L., Hart, J.R., et al. A small molecule RAS-mimetic disrupts RAS association with effector proteins to block signaling. Cell 165 (2016), 643–655.
7. Ballester, R., Furth, M.E., Rosen, O.M., Phorbol ester- and protein kinase C-mediated phosphorylation of the cellular Kirsten ras gene product. J. Biol. Chem. 262 (1987), 2688–2695.
8. Barretina, J., Taylor, B.S., Banerji, S., Ramos, A.H., Lagos-Quintana, M., Decarolis, P.L., Shah, K., Socci, N.D., Weir, B.A., Ho, A., et al. Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat. Genet. 42 (2010), 715–721.
9. Bayrak-Toydemir, P., Stevenson, D., RASA1-related disorders. Pagon, R.A., Adam, M.P., Ardinger, H.H., Wallace, S.E., Amemiya, A., Bean, L.J.H., Bird, T.D., Ledbetter, N., Mefford, H.C., Smith, R.J.H., et al. (eds.) GeneReviews(R), 1993, University of Washington, Seattle.
10. Bernards, A., GAPs galore! A survey of putative Ras superfamily GTPase activating proteins in man and Drosophila. Biochim. Biophys. Acta 1603 (2003), 47–82.
11. Bivona, T.G., Quatela, S.E., Bodemann, B.O., Ahearn, I.M., Soskis, M.J., Mor, A., Miura, J., Wiener, H.H., Wright, L., Saba, S.G., et al. PKC regulates a farnesyl-electrostatic switch on K-Ras that promotes its association with Bcl-XL on mitochondria and induces apoptosis. Mol. Cell 21 (2006), 481–493.
12. Boriack-Sjodin, P.A., Margarit, S.M., Bar-Sagi, D., Kuriyan, J., The structural basis of the activation of Ras by Sos. Nature 394 (1998), 337–343.
13. Bos, J.L., Rehmann, H., Wittinghofer, A., GEFs and GAPs: critical elements in the control of small G proteins. Cell 129 (2007), 865–877.
14. Boyartchuk, V.L., Ashby, M.N., Rine, J., Modulation of Ras and a-factor function by carboxyl-terminal proteolysis. Science 275 (1997), 1796–1800.
15. Boyd, K.P., Gao, L., Feng, R., Beasley, M., Messiaen, L., Korf, B.R., Theos, A., Phenotypic variability among café-au-lait macules in neurofibromatosis type 1. J. Am. Acad. Dermatol. 63 (2010), 440–447.
16. Brasil, A.S., Malaquias, A.C., Wanderley, L.T., Kim, C.A., Krieger, J.E., Jorge, A.A., Pereira, A.C., Bertola, D.R., Co-occurring PTPN11 and SOS1 gene mutations in Noonan syndrome: does this predict a more severe phenotype?. Arq. Bras. Endocrinol. Metabol. 54 (2010), 717–722.
17. Brasil, A.S., Pereira, A.C., Wanderley, L.T., Kim, C.A., Malaquias, A.C., Jorge, A.A., Krieger, J.E., Bertola, D.R., PTPN11 and KRAS gene analysis in patients with Noonan and Noonan-like syndromes. Genet. Test. Mol. Biomarkers 14 (2010), 425–432.
18. Bremner, R., Balmain, A., Genetic changes in skin tumor progression: correlation between presence of a mutant ras gene and loss of heterozygosity on mouse chromosome 7. Cell 61 (1990), 407–417.
19. Brems, H., Chmara, M., Sahbatou, M., Denayer, E., Taniguchi, K., Kato, R., Somers, R., Messiaen, L., De Schepper, S., Fryns, J.P., et al. Germline loss-of-function mutations in SPRED1 cause a neurofibromatosis 1-like phenotype. Nat. Genet. 39 (2007), 1120–1126.
20. Brennan, C., Momota, H., Hambardzumyan, D., Ozawa, T., Tandon, A., Pedraza, A., Holland, E., Glioblastoma subclasses can be defined by activity among signal transduction pathways and associated genomic alterations. PLoS ONE, 4, 2009, e7752.
21. Burns, M.C., Sun, Q., Daniels, R.N., Camper, D., Kennedy, J.P., Phan, J., Olejniczak, E.T., Lee, T., Waterson, A.G., Rossanese, O.W., Fesik, S.W., Approach for targeting Ras with small molecules that activate SOS-mediated nucleotide exchange. Proc. Natl. Acad. Sci. USA 111 (2014), 3401–3406.
22. Campbell, J.D., Alexandrov, A., Kim, J., Wala, J., Berger, A.H., Pedamallu, C.S., Shukla, S.A., Guo, G., Brooks, A.N., Murray, B.A., et al., Cancer Genome Atlas Research Network. Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas. Nat. Genet. 48 (2016), 607–616.
23. Castellano, E., Downward, J., RAS interaction with PI3K: more than just another effector pathway. Genes Cancer 2 (2011), 261–274.
24. Castellano, E., Sheridan, C., Thin, M.Z., Nye, E., Spencer-Dene, B., Diefenbacher, M.E., Moore, C., Kumar, M.S., Murillo, M.M., Grönroos, E., et al. Requirement for interaction of PI3-kinase p110α with RAS in lung tumor maintenance. Cancer Cell 24 (2013), 617–630.
25. Chandra, A., Grecco, H.E., Pisupati, V., Perera, D., Cassidy, L., Skoulidis, F., Ismail, S.A., Hedberg, C., Hanzal-Bayer, M., Venkitaraman, A.R., et al. The GDI-like solubilizing factor PDEδ sustains the spatial organization and signalling of Ras family proteins. Nat. Cell Biol. 14 (2011), 148–158.
26. Chang, T., Krisman, K., Theobald, E.H., Xu, J., Akutagawa, J., Lauchle, J.O., Kogan, S., Braun, B.S., Shannon, K., Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice. J. Clin. Invest. 123 (2013), 335–339.
27. Cherfils, J., Zeghouf, M., Regulation of small GTPases by GEFs, GAPs, and GDIs. Physiol. Rev. 93 (2013), 269–309.
28. Chio, I.I., Jafarnejad, S.M., Ponz-Sarvise, M., Park, Y., Rivera, K., Palm, W., Wilson, J., Sangar, V., Hao, Y., Öhlund, D., et al. NRF2 promotes tumor maintenance by modulating mRNA translation in pancreatic cancer. Cell 166 (2016), 963–976.
29. Cordeddu, V., Di Schiavi, E., Pennacchio, L.A., Ma'ayan, A., Sarkozy, A., Fodale, V., Cecchetti, S., Cardinale, A., Martin, J., Schackwitz, W., et al. Mutation of SHOC2 promotes aberrant protein N-myristoylation and causes Noonan-like syndrome with loose anagen hair. Nat. Genet. 41 (2009), 1022–1026.
30. Dai, Q., Choy, E., Chiu, V., Romano, J., Slivka, S.R., Steitz, S.A., Michaelis, S., Philips, M.R., Mammalian prenylcysteine carboxyl methyltransferase is in the endoplasmic reticulum. J. Biol. Chem. 273 (1998), 15030–15034.
31. de Bruin, E.C., Cowell, C., Warne, P.H., Jiang, M., Saunders, R.E., Melnick, M.A., Gettinger, S., Walther, Z., Wurtz, A., Heynen, G.J., et al. Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer. Cancer Discov. 4 (2014), 606–619.
32. Dharmaiah, S., Bindu, L., Tran, T.H., Gillette, W.K., Frank, P.H., Ghirlando, R., Nissley, D.V., Esposito, D., McCormick, F., Stephen, A.G., Simanshu, D.K., Structural basis of recognition of farnesylated and methylated KRAS4b by PDEδ. Proc. Natl. Acad. Sci. USA 113 (2016), E6766–E6775.
33. Dombi, E., Baldwin, A., Marcus, L.J., Fisher, M.J., Weiss, B., Kim, A., Whitcomb, P., Martin, S., Aschbacher-Smith, L.E., Rizvi, T.A., et al. Activity of selumetinib in neurofibromatosis type 1-related plexiform neurofibromas. N. Engl. J. Med. 375 (2016), 2550–2560.
34. Downward, J., RAS Synthetic Lethal Screens Revisited: Still Seeking the Elusive Prize?. Clin. Cancer Res. 21 (2015), 1802–1809.
35. Drosten, M., Dhawahir, A., Sum, E.Y., Urosevic, J., Lechuga, C.G., Esteban, L.M., Castellano, E., Guerra, C., Santos, E., Barbacid, M., Genetic analysis of Ras signalling pathways in cell proliferation, migration and survival. EMBO J. 29 (2010), 1091–1104.
36. Dunzendorfer-Matt, T., Mercado, E.L., Maly, K., McCormick, F., Scheffzek, K., The neurofibromin recruitment factor Spred1 binds to the GAP related domain without affecting Ras inactivation. Proc. Natl. Acad. Sci. USA 113 (2016), 7497–7502.
37. Easton, D.F., Ponder, M.A., Huson, S.M., Ponder, B.A., An analysis of variation in expression of neurofibromatosis (NF) type 1 (NF1): evidence for modifying genes. Am. J. Hum. Genet. 53 (1993), 305–313.
38. Edkins, S., O'Meara, S., Parker, A., Stevens, C., Reis, M., Jones, S., Greenman, C., Davies, H., Dalgliesh, G., Forbes, S., et al. Recurrent KRAS codon 146 mutations in human colorectal cancer. Cancer Biol. Ther. 5 (2006), 928–932.
39. Ekvall, S., Hagenäs, L., Allanson, J., Annerén, G., Bondeson, M.L., Co-occurring SHOC2 and PTPN11 mutations in a patient with severe/complex Noonan syndrome-like phenotype. Am. J. Med. Genet. A. 155A (2011), 1217–1224.
40. Erwin, N., Sperlich, B., Garivet, G., Waldmann, H., Weise, K., Winter, R., Lipoprotein insertion into membranes of various complexity: lipid sorting, interfacial adsorption and protein clustering. Phys. Chem. Chem. Phys. 18 (2016), 8954–8962.
41. Ferro, E., Trabalzini, L., RalGDS family members couple Ras to Ral signalling and that's not all. Cell. Signal. 22 (2010), 1804–1810.
42. Fivaz, M., Meyer, T., Reversible intracellular translocation of KRas but not HRas in hippocampal neurons regulated by Ca2+/calmodulin. J. Cell Biol. 170 (2005), 429–441.
43. Freeman, A.K., Ritt, D.A., Morrison, D.K., The importance of Raf dimerization in cell signaling. Small GTPases 4 (2013), 180–185.
44. García-Romero, M.T., Parkin, P., Lara-Corrales, I., Mosaic neurofibromatosis type 1: a systematic review. Pediatr. Dermatol. 33 (2016), 9–17.
45. Grabocka, E., Pylayeva-Gupta, Y., Jones, M.J., Lubkov, V., Yemanaberhan, E., Taylor, L., Jeng, H.H., Bar-Sagi, D., Wild-type H- and N-Ras promote mutant K-Ras-driven tumorigenesis by modulating the DNA damage response. Cancer Cell 25 (2014), 243–256.
46. Gripp, K.W., Aldinger, K.A., Bennett, J.T., Baker, L., Tusi, J., Powell-Hamilton, N., Stabley, D., Sol-Church, K., Timms, A.E., Dobyns, W.B., A novel rasopathy caused by recurrent de novo missense mutations in PPP1CB closely resembles Noonan syndrome with loose anagen hair. Am. J. Med. Genet. A. 170 (2016), 2237–2247.
47. Güldenhaupt, J., Rudack, T., Bachler, P., Mann, D., Triola, G., Waldmann, H., Kötting, C., Gerwert, K., N-Ras forms dimers at POPC membranes. Biophys. J. 103 (2012), 1585–1593.
48. Gupta, S., Ramjaun, A.R., Haiko, P., Wang, Y., Warne, P.H., Nicke, B., Nye, E., Stamp, G., Alitalo, K., Downward, J., Binding of ras to phosphoinositide 3-kinase p110alpha is required for ras-driven tumorigenesis in mice. Cell 129 (2007), 957–968.
49. Gutierrez, L., Magee, A.I., Marshall, C.J., Hancock, J.F., Post-translational processing of p21ras is two-step and involves carboxyl-methylation and carboxy-terminal proteolysis. EMBO J. 8 (1989), 1093–1098.
50. Haigis, K.M., Kendall, K.R., Wang, Y., Cheung, A., Haigis, M.C., Glickman, J.N., Niwa-Kawakita, M., Sweet-Cordero, A., Sebolt-Leopold, J., Shannon, K.M., et al. Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. Nat. Genet. 40 (2008), 600–608.
51. Hancock, J.F., Magee, A.I., Childs, J.E., Marshall, C.J., All ras proteins are polyisoprenylated but only some are palmitoylated. Cell 57 (1989), 1167–1177.
52. Hancock, J.F., Cadwallader, K., Marshall, C.J., Methylation and proteolysis are essential for efficient membrane binding of prenylated p21K-ras(B). EMBO J. 10 (1991), 641–646.
53. Higgins, E.M., Bos, J.M., Mason-Suares, H., Tester, D.J., Ackerman, J.P., MacRae, C.A., Sol-Church, K., Gripp, K.W., Urrutia, R., Ackerman, M.J., Elucidation of MRAS-mediated Noonan syndrome with cardiac hypertrophy. JCI Insight, 2, 2017, e91225.
54. Holderfield, M., Deuker, M.M., McCormick, F., McMahon, M., Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond. Nat. Rev. Cancer 14 (2014), 455–467.
55. Howard, T.P., Vazquez, F., Tsherniak, A., Hong, A.L., Rinne, M., Aguirre, A.J., Boehm, J.S., Hahn, W.C., Functional genomic characterization of cancer genomes. Cold Spring Harb. Symp. Quant. Biol., 2016, 031070.
56. Hunter, J.C., Manandhar, A., Carrasco, M.A., Gurbani, D., Gondi, S., Westover, K.D., Biochemical and structural analysis of common cancer-associated KRAS mutations. Mol. Cancer Res. 13 (2015), 1325–1335.
57. Huntley, C., Hodder, A., Ramachandran, M., Clinical and historical aspects of the Elephant Man: exploring the facts and the myths. Gene 555 (2015), 63–65.
58. Inouye, K., Mizutani, S., Koide, H., Kaziro, Y., Formation of the Ras dimer is essential for Raf-1 activation. J. Biol. Chem. 275 (2000), 3737–3740.
59. Jackson, J.H., Cochrane, C.G., Bourne, J.R., Solski, P.A., Buss, J.E., Der, C.J., Farnesol modification of Kirsten-ras exon 4B protein is essential for transformation. Proc. Natl. Acad. Sci. USA 87 (1990), 3042–3046.
60. Jang, H., Banerjee, A., Chavan, T.S., Lu, S., Zhang, J., Gaponenko, V., Nussinov, R., The higher level of complexity of K-Ras4B activation at the membrane. FASEB J. 30 (2016), 1643–1655.
61. Jessen, W.J., Miller, S.J., Jousma, E., Wu, J., Rizvi, T.A., Brundage, M.E., Eaves, D., Widemann, B., Kim, M.O., Dombi, E., et al. MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors. J. Clin. Invest. 123 (2013), 340–347.
62. Jeyabalan, N., Clement, J.P., SYNGAP1: mind the gap. Front. Cell. Neurosci., 10, 2016, 32.
63. Kaplan, D.R., Morrison, D.K., Wong, G., McCormick, F., Williams, L.T., PDGF beta-receptor stimulates tyrosine phosphorylation of GAP and association of GAP with a signaling complex. Cell 61 (1990), 125–133.
64. Kapoor, S., Weise, K., Erlkamp, M., Triola, G., Waldmann, H., Winter, R., The role of G-domain orientation and nucleotide state on the Ras isoform-specific membrane interaction. Eur. Biophys. J. 41 (2012), 801–813.
65. Kapoor, A., Yao, W., Ying, H., Hua, S., Liewen, A., Wang, Q., Zhong, Y., Wu, C.J., Sadanandam, A., Hu, B., et al. Yap1 activation enables bypass of oncogenic Kras addiction in pancreatic cancer. Cell 158 (2014), 185–197.
66. Keppler-Noreuil, K.M., Parker, V.E., Darling, T.N., Martinez-Agosto, J.A., Somatic overgrowth disorders of the PI3K/AKT/mTOR pathway & therapeutic strategies. Am. J. Med. Genet. C. Semin. Med. Genet. 172 (2016), 402–421.
67. Kim, J., McMillan, E., Kim, H.S., Venkateswaran, N., Makkar, G., Rodriguez-Canales, J., Villalobos, P., Neggers, J.E., Mendiratta, S., Wei, S., et al. XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer. Nature 538 (2016), 114–117.
68. Kohl, N.E., Omer, C.A., Conner, M.W., Anthony, N.J., Davide, J.P., deSolms, S.J., Giuliani, E.A., Gomez, R.P., Graham, S.L., Hamilton, K., et al. Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice. Nat. Med. 1 (1995), 792–797.
69. Krauthammer, M., Kong, Y., Bacchiocchi, A., Evans, P., Pornputtapong, N., Wu, C., McCusker, J.P., Ma, S., Cheng, E., Straub, R., et al. Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas. Nat. Genet. 47 (2015), 996–1002.
70. Lake, D., Corrêa, S.A., Müller, J., Negative feedback regulation of the ERK1/2 MAPK pathway. Cell. Mol. Life Sci. 73 (2016), 4397–4413.
71. Leevers, S.J., Paterson, H.F., Marshall, C.J., Requirement for Ras in Raf activation is overcome by targeting Raf to the plasma membrane. Nature 369 (1994), 411–414.
72. Li, H.F., Wu, Z.Y., Genotype-phenotype correlations of amyotrophic lateral sclerosis. Transl. Neurodegener., 5, 2016, 3.
73. Lin, W.C., Iversen, L., Tu, H.L., Rhodes, C., Christensen, S.M., Iwig, J.S., Hansen, S.D., Huang, W.Y., Groves, J.T., H-Ras forms dimers on membrane surfaces via a protein-protein interface. Proc. Natl. Acad. Sci. USA 111 (2014), 2996–3001.
74. Lobell, R.B., Liu, D., Buser, C.A., Davide, J.P., DePuy, E., Hamilton, K., Koblan, K.S., Lee, Y., Mosser, S., Motzel, S.L., et al. Preclinical and clinical pharmacodynamic assessment of L-778,123, a dual inhibitor of farnesyl:protein transferase and geranylgeranyl:protein transferase type-I. Mol. Cancer Ther. 1 (2002), 747–758.
75. Lusk, J.B., Lam, V.Y., Tolwinski, N.S., Epidermal growth factor pathway signaling in Drosophila embryogenesis: tools for understanding cancer. Cancers (Basel), 9, 2017, E16.
76. Martin, G.A., Viskochil, D., Bollag, G., McCabe, P.C., Crosier, W.J., Haubruck, H., Conroy, L., Clark, R., O'Connell, P., Cawthon, R.M., et al. The GAP-related domain of the neurofibromatosis type 1 gene product interacts with ras p21. Cell 63 (1990), 843–849.
77. Maurer, T., Garrenton, L.S., Oh, A., Pitts, K., Anderson, D.J., Skelton, N.J., Fauber, B.P., Pan, B., Malek, S., Stokoe, D., et al. Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity. Proc. Natl. Acad. Sci. USA 109 (2012), 5299–5304.
78. Mazhab-Jafari, M.T., Marshall, C.B., Smith, M.J., Gasmi-Seabrook, G.M., Stathopulos, P.B., Inagaki, F., Kay, L.E., Neel, B.G., Ikura, M., Oncogenic and RASopathy-associated K-RAS mutations relieve membrane-dependent occlusion of the effector-binding site. Proc. Natl. Acad. Sci. USA 112 (2015), 6625–6630.
79. McGillicuddy, L.T., Fromm, J.A., Hollstein, P.E., Kubek, S., Beroukhim, R., De Raedt, T., Johnson, B.W., Williams, S.M., Nghiemphu, P., Liau, L.M., et al. Proteasomal and genetic inactivation of the NF1 tumor suppressor in gliomagenesis. Cancer Cell 16 (2009), 44–54.
80. McLaughlin, S.K., Olsen, S.N., Dake, B., De Raedt, T., Lim, E., Bronson, R.T., Beroukhim, R., Polyak, K., Brown, M., Kuperwasser, C., Cichowski, K., The RasGAP gene, RASAL2, is a tumor and metastasis suppressor. Cancer Cell 24 (2013), 365–378.
81. Mignot, C., von Stülpnagel, C., Nava, C., Ville, D., Sanlaville, D., Lesca, G., Rastetter, A., Gachet, B., Marie, Y., Korenke, G.C., et al., EuroEPINOMICS-RES MAE working group. Genetic and neurodevelopmental spectrum of SYNGAP1-associated intellectual disability and epilepsy. J. Med. Genet. 53 (2016), 511–522.
82. Milburn, M.V., Tong, L., deVos, A.M., Brünger, A., Yamaizumi, Z., Nishimura, S., Kim, S.H., Molecular switch for signal transduction: structural differences between active and inactive forms of protooncogenic ras proteins. Science 247 (1990), 939–945.
83. Min, J., Zaslavsky, A., Fedele, G., McLaughlin, S.K., Reczek, E.E., De Raedt, T., Guney, I., Strochlic, D.E., Macconaill, L.E., Beroukhim, R., et al. An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-kappaB. Nat. Med. 16 (2010), 286–294.
84. Morris, S.M., Acosta, M.T., Garg, S., Green, J., Huson, S., Legius, E., North, K.N., Payne, J.M., Plasschaert, E., Frazier, T.W., et al. Disease burden and symptom structure of autism in neurofibromatosis type 1: a study of the International NF1-ASD Consortium Team (INFACT). JAMA Psychiatry 73 (2016), 1276–1284.
85. Mott, H.R., Owen, D., Structures of Ras superfamily effector complexes: What have we learnt in two decades?. Crit. Rev. Biochem. Mol. Biol. 50 (2015), 85–133.
86. Murillo, M.M., Zelenay, S., Nye, E., Castellano, E., Lassailly, F., Stamp, G., Downward, J., RAS interaction with PI3K p110α is required for tumor-induced angiogenesis. J. Clin. Invest. 124 (2014), 3601–3611.
87. Nan, X., Tamgüney, T.M., Collisson, E.A., Lin, L.J., Pitt, C., Galeas, J., Lewis, S., Gray, J.W., McCormick, F., Chu, S., Ras-GTP dimers activate the mitogen-activated protein kinase (MAPK) pathway. Proc. Natl. Acad. Sci. USA 112 (2015), 7996–8001.
88. Ohba, Y., Mochizuki, N., Yamashita, S., Chan, A.M., Schrader, J.W., Hattori, S., Nagashima, K., Matsuda, M., Regulatory proteins of R-Ras, TC21/R-Ras2, and M-Ras/R-Ras3. J. Biol. Chem. 275 (2000), 20020–20026.
89. Olsen, S.N., Wronski, A., Castano, Z., Dake, B., Malone, C., De Raedt, T., Enos, M., DeRose, Y.S., Zhou, W., Guerra, S., et al. Loss of RasGAP tumor suppressors underlie the aggressive nature of luminal B breast cancers. Cancer Discov. 7 (2016), 202–217.
90. Ostrem, J.M., Shokat, K.M., Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design. Nat. Rev. Drug Discov. 15 (2016), 771–785.
91. Ostrem, J.M., Peters, U., Sos, M.L., Wells, J.A., Shokat, K.M., K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature 503 (2013), 548–551.
92. Pacold, M.E., Suire, S., Perisic, O., Lara-Gonzalez, S., Davis, C.T., Walker, E.H., Hawkins, P.T., Stephens, L., Eccleston, J.F., Williams, R.L., Crystal structure and functional analysis of Ras binding to its effector phosphoinositide 3-kinase gamma. Cell 103 (2000), 931–943.
93. Pai, E.F., Kabsch, W., Krengel, U., Holmes, K.C., John, J., Wittinghofer, A., Structure of the guanine-nucleotide-binding domain of the Ha-ras oncogene product p21 in the triphosphate conformation. Nature 341 (1989), 209–214.
94. Papke, B., Murarka, S., Vogel, H.A., Martín-Gago, P., Kovacevic, M., Truxius, D.C., Fansa, E.K., Ismail, S., Zimmermann, G., Heinelt, K., et al. Identification of pyrazolopyridazinones as PDEδ inhibitors. Nat. Commun., 7, 2016, 11360.
95. Patricelli, M.P., Janes, M.R., Li, L.S., Hansen, R., Peters, U., Kessler, L.V., Chen, Y., Kucharski, J.M., Feng, J., Ely, T., et al. Selective inhibition of oncogenic KRAS output with small molecules targeting the inactive state. Cancer Discov. 6 (2016), 316–329.
96. Paulson, V.A., Shivdasani, P., Angell, T.E., Alexander, E.K., Cibas, E., Krane, J.F., Lindeman, N.I., Barletta, J., NIFTP accounts for over half of “carcinomas” harboring RAS mutations. Thyroid 27 (2017), 506–511.
97. Powers, S., Genetic analysis of ras homologs in yeasts. Semin. Cancer Biol. 3 (1992), 209–218.
98. Prakash, P., Gorfe, A.A., Membrane orientation dynamics of lipid-modified small GTPases. Small GTPases Aug 11 (2016), 1–10.
99. Prakash, P., Sayyed-Ahmad, A., Gorfe, A.A., pMD-membrane: a method for ligand binding site identification in membrane-bound proteins. PLoS Comput. Biol., 11, 2015, e1004469.
100. Prakash, P., Zhou, Y., Liang, H., Hancock, J.F., Gorfe, A.A., Oncogenic K-Ras binds to an anionic membrane in two distinct orientations: a molecular dynamics analysis. Biophys. J. 110 (2016), 1125–1138.
101. Quinlan, M.P., Quatela, S.E., Philips, M.R., Settleman, J., Activated Kras, but not Hras or Nras, may initiate tumors of endodermal origin via stem cell expansion. Mol. Cell. Biol. 28 (2008), 2659–2674.
102. Raaijmakers, J.H., Bos, J.L., Specificity in Ras and Rap signaling. J. Biol. Chem. 284 (2009), 10995–10999.
103. Rauen, K.A., HRAS and the Costello syndrome. Clin. Genet. 71 (2007), 101–108.
104. Ritt, D.A., Abreu-Blanco, M.T., Bindu, L., Durrant, D.E., Zhou, M., Specht, S.I., Stephen, A.G., Holderfield, M., Morrison, D.K., Inhibition of Ras/Raf/MEK/ERK Pathway Signaling by a Stress-Induced Phospho-Regulatory Circuit. Mol. Cell 64 (2016), 875–887.
105. Rodriguez-Viciana, P., Sabatier, C., McCormick, F., Signaling specificity by Ras family GTPases is determined by the full spectrum of effectors they regulate. Mol. Cell. Biol. 24 (2004), 4943–4954.
106. Rodriguez-Viciana, P., Oses-Prieto, J., Burlingame, A., Fried, M., McCormick, F., A phosphatase holoenzyme comprised of Shoc2/Sur8 and the catalytic subunit of PP1 functions as an M-Ras effector to modulate Raf activity. Mol. Cell 22 (2006), 217–230.
107. Rosenberg, S.A., Tran, E., Robbins, P.F., T-cell transfer therapy targeting mutant KRAS. N. Engl. J. Med., 376, 2017, e11.
108. Rotblat, B., Prior, I.A., Muncke, C., Parton, R.G., Kloog, Y., Henis, Y.I., Hancock, J.F., Three separable domains regulate GTP-dependent association of H-ras with the plasma membrane. Mol. Cell. Biol. 24 (2004), 6799–6810.
109. Rowell, C.A., Kowalczyk, J.J., Lewis, M.D., Garcia, A.M., Direct demonstration of geranylgeranylation and farnesylation of Ki-Ras in vivo. J. Biol. Chem. 272 (1997), 14093–14097.
110. Scheffzek, K., Ahmadian, M.R., Kabsch, W., Wiesmüller, L., Lautwein, A., Schmitz, F., Wittinghofer, A., The Ras-RasGAP complex: structural basis for GTPase activation and its loss in oncogenic Ras mutants. Science 277 (1997), 333–338.
111. Schmick, M., Vartak, N., Papke, B., Kovacevic, M., Truxius, D.C., Rossmannek, L., Bastiaens, P.I., KRas localizes to the plasma membrane by spatial cycles of solubilization, trapping and vesicular transport. Cell 157 (2014), 459–471.
112. Schubbert, S., Zenker, M., Rowe, S.L., Böll, S., Klein, C., Bollag, G., van der Burgt, I., Musante, L., Kalscheuer, V., Wehner, L.E., et al. Germline KRAS mutations cause Noonan syndrome. Nat. Genet. 38 (2006), 331–336.
113. Settleman, J., Narasimhan, V., Foster, L.C., Weinberg, R.A., Molecular cloning of cDNAs encoding the GAP-associated protein p190: implications for a signaling pathway from ras to the nucleus. Cell 69 (1992), 539–549.
114. Shain, A.H., Garrido, M., Botton, T., Talevich, E., Yeh, I., Sanborn, J.Z., Chung, J., Wang, N.J., Kakavand, H., Mann, G.J., et al. Exome sequencing of desmoplastic melanoma identifies recurrent NFKBIE promoter mutations and diverse activating mutations in the MAPK pathway. Nat. Genet. 47 (2015), 1194–1199.
115. Shao, D.D., Xue, W., Krall, E.B., Bhutkar, A., Piccioni, F., Wang, X., Schinzel, A.C., Sood, S., Rosenbluh, J., Kim, J.W., et al. KRAS and YAP1 converge to regulate EMT and tumor survival. Cell 158 (2014), 171–184.
116. Spencer-Smith, R., Koide, A., Zhou, Y., Eguchi, R.R., Sha, F., Gajwani, P., Santana, D., Gupta, A., Jacobs, M., Herrero-Garcia, E., et al. Inhibition of RAS function through targeting an allosteric regulatory site. Nat. Chem. Biol. 13 (2017), 62–68.
117. Sperlich, B., Kapoor, S., Waldmann, H., Winter, R., Weise, K., Regulation of K-Ras4B membrane binding by calmodulin. Biophys. J. 111 (2016), 113–122.
118. Stenson, P.D., Ball, E., Howells, K., Phillips, A., Mort, M., Cooper, D.N., Human Gene Mutation Database: towards a comprehensive central mutation database. J. Med. Genet. 45 (2008), 124–126.
119. Stephen, A.G., Esposito, D., Bagni, R.K., McCormick, F., Dragging ras back in the ring. Cancer Cell 25 (2014), 272–281.
120. Stokoe, D., Macdonald, S.G., Cadwallader, K., Symons, M., Hancock, J.F., Activation of Raf as a result of recruitment to the plasma membrane. Science 264 (1994), 1463–1467.
121. Stowe, I.B., Mercado, E.L., Stowe, T.R., Bell, E.L., Oses-Prieto, J.A., Hernández, H., Burlingame, A.L., McCormick, F., A shared molecular mechanism underlies the human rasopathies Legius syndrome and Neurofibromatosis-1. Genes Dev. 26 (2012), 1421–1426.
122. Sun, Q., Burke, J.P., Phan, J., Burns, M.C., Olejniczak, E.T., Waterson, A.G., Lee, T., Rossanese, O.W., Fesik, S.W., Discovery of small molecules that bind to K-Ras and inhibit Sos-mediated activation. Angew. Chem. Int. Ed. Engl. 51 (2012), 6140–6143.
123. Sung, P.J., Tsai, F.D., Vais, H., Court, H., Yang, J., Fehrenbacher, N., Foskett, J.K., Philips, M.R., Phosphorylated K-Ras limits cell survival by blocking Bcl-xL sensitization of inositol trisphosphate receptors. Proc. Natl. Acad. Sci. USA 110 (2013), 20593–20598.
124. Swarthout, J.T., Lobo, S., Farh, L., Croke, M.R., Greentree, W.K., Deschenes, R.J., Linder, M.E., DHHC9 and GCP16 constitute a human protein fatty acyltransferase with specificity for H- and N-Ras. J. Biol. Chem. 280 (2005), 31141–31148.
125. Thiel, C., Wilken, M., Zenker, M., Sticht, H., Fahsold, R., Gusek-Schneider, G.C., Rauch, A., Independent NF1 and PTPN11 mutations in a family with neurofibromatosis-i syndrome. Am. J. Med. Genet. A. 149A (2009), 1263–1267.
126. Tidyman, W.E., Rauen, K.A., Pathogenetics of the RASopathies. Hum. Mol. Genet. 25:R2 (2016), R123–R132.
127. To, M.D., Wong, C.E., Karnezis, A.N., Del Rosario, R., Di Lauro, R., Balmain, A., Kras regulatory elements and exon 4A determine mutation specificity in lung cancer. Nat. Genet. 40 (2008), 1240–1244.
128. To, M.D., Rosario, R.D., Westcott, P.M., Banta, K.L., Balmain, A., Interactions between wild-type and mutant Ras genes in lung and skin carcinogenesis. Oncogene 32 (2013), 4028–4033.
129. Trahey, M., McCormick, F., A cytoplasmic protein stimulates normal N-ras p21 GTPase, but does not affect oncogenic mutants. Science 238 (1987), 542–545.
130. Ullrich, M., Weber, M., Post, A.M., Popp, S., Grein, J., Zechner, M., Guerrero González, H., Kreis, A., Schmitt, A.G., Üçeyler, N., et al. OCD-like behavior is caused by dysfunction of thalamo-amygdala circuits and upregulated TrkB/ERK-MAPK signaling as a result of SPRED2 deficiency. Mol. Psychiatry, 2017, 10.1038/mp.2016.232.
131. Uusitalo, E., Rantanen, M., Kallionpää, R.A., Pöyhönen, M., Leppävirta, J., Ylä-Outinen, H., Riccardi, V.M., Pukkala, E., Pitkäniemi, J., Peltonen, S., Peltonen, J., Distinctive cancer associations in patients with neurofibromatosis type 1. J. Clin. Oncol. 34 (2016), 1978–1986.
132. Vetter, I.R., Wittinghofer, A., The guanine nucleotide-binding switch in three dimensions. Science 294 (2001), 1299–1304.
133. Villalonga, P., López-Alcalá, C., Bosch, M., Chiloeches, A., Rocamora, N., Gil, J., Marais, R., Marshall, C.J., Bachs, O., Agell, N., Calmodulin binds to K-Ras, but not to H- or N-Ras, and modulates its downstream signaling. Mol. Cell. Biol. 21 (2001), 7345–7354.
134. Vogel, A., Reuther, G., Weise, K., Triola, G., Nikolaus, J., Tan, K.T., Nowak, C., Herrmann, A., Waldmann, H., Winter, R., Huster, D., The lipid modifications of Ras that sense membrane environments and induce local enrichment. Angew. Chem. Int. Ed. Engl. 48 (2009), 8784–8787.
135. Wang, M.T., Holderfield, M., Galeas, J., Delrosario, R., To, M.D., Balmain, A., McCormick, F., K-Ras promotes tumorigenicity through suppression of non-canonical Wnt signaling. Cell 163 (2015), 1237–1251.
136. Wang, T., Yu, H., Hughes, N.W., Liu, B., Kendirli, A., Klein, K., Chen, W.W., Lander, E.S., Sabatini, D.M., Gene essentiality profiling reveals gene networks and synthetic lethal interactions with oncogenic Ras. Cell 168 (2017), 890–903.
137. Weise, K., Triola, G., Brunsveld, L., Waldmann, H., Winter, R., Influence of the lipidation motif on the partitioning and association of N-Ras in model membrane subdomains. J. Am. Chem. Soc. 131 (2009), 1557–1564.
138. Weise, K., Kapoor, S., Denter, C., Nikolaus, J., Opitz, N., Koch, S., Triola, G., Herrmann, A., Waldmann, H., Winter, R., Membrane-mediated induction and sorting of K-Ras microdomain signaling platforms. J. Am. Chem. Soc. 133 (2011), 880–887.
139. Westcott, P.M., Halliwill, K.D., To, M.D., Rashid, M., Rust, A.G., Keane, T.M., Delrosario, R., Jen, K.Y., Gurley, K.E., Kemp, C.J., et al. The mutational landscapes of genetic and chemical models of Kras-driven lung cancer. Nature 517 (2015), 489–492.
140. Whyte, D.B., Kirschmeier, P., Hockenberry, T.N., Nunez-Oliva, I., James, L., Catino, J.J., Bishop, W.R., Pai, J.K., K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J. Biol. Chem. 272 (1997), 14459–14464.
141. Williams, V.L., Cohen, P.R., Stewart, D.J., Sorafenib-induced premalignant and malignant skin lesions. Int. J. Dermatol. 50 (2011), 396–402.
142. Willumsen, B.M., Christensen, A., Hubbert, N.L., Papageorge, A.G., Lowy, D.R., The p21 ras C-terminus is required for transformation and membrane association. Nature 310 (1984), 583–586.
143. Xiong, Y., Lu, J., Hunter, J., Li, L., Scott, D., Choi, H.G., Lim, S.M., Manandhar, A., Gondi, S., Sim, T., et al. Covalent guanosine mimetic inhibitors of G12C KRAS. ACS Med. Chem. Lett. 8 (2016), 61–66.
144. Xu, G.F., Lin, B., Tanaka, K., Dunn, D., Wood, D., Gesteland, R., White, R., Weiss, R., Tamanoi, F., The catalytic domain of the neurofibromatosis type 1 gene product stimulates ras GTPase and complements ira mutants of S. cerevisiae. Cell 63 (1990), 835–841.
145. Xu, J., Haigis, K.M., Firestone, A.J., McNerney, M.E., Li, Q., Davis, E., Chen, S.C., Nakitandwe, J., Downing, J., Jacks, T., et al. Dominant role of oncogene dosage and absence of tumor suppressor activity in Nras-driven hematopoietic transformation. Cancer Discov. 3 (2013), 993–1001.
146. Young, A., Lou, D., McCormick, F., Oncogenic and wild-type Ras play divergent roles in the regulation of mitogen-activated protein kinase signaling. Cancer Discov. 3 (2013), 112–123.
147. Young, L.C., Hartig, N., Muñoz-Alegre, M., Oses-Prieto, J.A., Durdu, S., Bender, S., Vijayakumar, V., Vietri Rudan, M., Gewinner, C., Henderson, S., et al. An MRAS, SHOC2, and SCRIB complex coordinates ERK pathway activation with polarity and tumorigenic growth. Mol. Cell 52 (2013), 679–692.
148. Yuan, T.L., Fellmann, C., Lee, C.S., Ritchie, C.D., Thapar, V., Lee, L.C., Hsu, D.J., Grace, D., Carver, J.O., Zuber, J., et al. Development of siRNA payloads to target KRAS-mutant cancer. Cancer Discov. 4 (2014), 1182–1197.
149. Zhang, Z., Wang, Y., Vikis, H.G., Johnson, L., Liu, G., Li, J., Anderson, M.W., Sills, R.C., Hong, H.L., Devereux, T.R., et al. Wildtype Kras2 can inhibit lung carcinogenesis in mice. Nat. Genet. 29 (2001), 25–33.
150. Zhang, C., Spevak, W., Zhang, Y., Burton, E.A., Ma, Y., Habets, G., Zhang, J., Lin, J., Ewing, T., Matusow, B., et al. RAF inhibitors that evade paradoxical MAPK pathway activation. Nature 526 (2015), 583–586.
151. Zhang, S.Y., Sperlich, B., Li, F.Y., Al-Ayoubi, S., Chen, H.X., Zhao, Y., Li, Y.M., Weise, K., Winter, R., Chen, Y.X., Phosphorylation weakens but does not inhibit membrane binding and clustering of K-Ras4B. ACS Chem. Biol., 2017, 10.1021/acschembio.7b00165.
152. Zhou, Y., Hancock, J.F., Ras nanoclusters: versatile lipid-based signaling platforms. Biochim. Biophys. Acta 1853 (2015), 841–849.
153. Zhou, Y., Prakash, P., Liang, H., Cho, K.J., Gorfe, A.A., Hancock, J.F., Lipid-sorting specificity encoded in K-Ras membrane anchor regulates signal output. Cell 168 (2017), 239–251.
154. Zhu, Y., Xu, J., Mei, X., Feng, Z., Zhang, L., Zhang, Q., Zhang, G., Zhu, W., Liu, J., Zhang, C., Biochemical and structural insights into the aminotransferase CrmG in Caerulomycin biosynthesis. ACS Chem. Biol. 11 (2016), 943–952.
155. Zimmermann, G., Papke, B., Ismail, S., Vartak, N., Chandra, A., Hoffmann, M., Hahn, S.A., Triola, G., Wittinghofer, A., Bastiaens, P.I.H., Waldmann, H., Small molecule inhibition of the KRAS-PDEδ interaction impairs oncogenic KRAS signalling. Nature 497 (2013), 638–642.